Selecta Biosciences, Inc. (SELB) financial statements (2021 and earlier)

Company profile

Business Address 480 ARSENAL WAY
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments90379784
Cash and cash equivalents90377159
Short-term investments  2625
Restricted cash and investments0 00
Receivables5 00
Other undisclosed current assets1522
Total current assets:97429987
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment1222
Restricted cash and investments1000
Other noncurrent assets   0
Total noncurrent assets:3222
TOTAL ASSETS:1004410189
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1413108
Accounts payable1124
Accrued liabilities131294
Deferred revenue2
Debt1921 4
Deferred revenue and credits12
Contract with customer, liability1
Total current liabilities:35351114
Noncurrent Liabilities
Long-term debt and lease obligation  218
Long-term debt, excluding current maturities  218
Liabilities, other than long-term debt15151713
Deferred revenue and credits1613
Deferred revenue15
Contract with customer, liability14
Deferred rent credit 0
Other liabilities 11 
Other undisclosed noncurrent liabilities42   
Total noncurrent liabilities:56153821
Total liabilities:91504934
Stockholders' equity
Stockholders' equity attributable to parent8(5)5255
Common stock0000
Additional paid in capital349280273211
Accumulated other comprehensive loss(5)(5)(4)(5)
Accumulated deficit(336)(280)(217)(152)
Receivable from shareholders or affiliates for issuance of capital stock   (0)
Total stockholders' equity:8(5)5255
TOTAL LIABILITIES AND EQUITY:1004410189

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit:7108
Operating expenses(59)(66)(64)(43)
Operating loss:(52)(65)(64)(35)
Nonoperating income (expense)(1)10(0)
Investment income, nonoperating1110
Foreign currency transaction gain (loss), before tax(0)0(0)(1)
Other nonoperating income (expense)(1)0(0)0
Interest and debt expense(2)(1)(2)(1)
Net loss:(54)(65)(65)(36)
Other undisclosed net loss attributable to parent(1)   
Net loss attributable to parent:(55)(65)(65)(36)
Preferred stock dividends and other adjustments   (5)
Net loss available to common stockholders, diluted:(55)(65)(65)(41)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(54)(65)(65)(36)
Other comprehensive income (loss) (0) 0
Comprehensive loss:(54)(65)(65)(36)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1) 0 
Comprehensive loss, net of tax, attributable to parent:(55)(65)(65)(36)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: